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Pivotal results of the Medtronic Vascular Talent
Thoracic Stent Graft System: The VALOR Trial
Ronald M. Fairman, MD,a Frank Criado,b Mark Farber, MD,c Christopher Kwolek, MD,d
Manish Mehta, MD,e Rodney White, MD,f Anthony Lee, MD,g and J. Michael Tuchek,h for the VALOR
Investigators, Philadelphia, Pa; Baltimore, Md; Chapel Hill, NC; Boston, Mass; Albany, NY; Torrance, Calif;
Gainesville, Fla; Maywood, Ill
Objective: This report summarizes the 30-day and 12-month results of endovascular treatment using the Medtronic
Vascular Talent Thoracic Stent Graft System (Medtronic Vascular, Santa Rosa, Calif) for patients with thoracic aortic
aneurysms (TAA) who are considered candidates for open surgical repair.
Methods: The study was a prospective, nonrandomized, multicenter, pivotal trial conducted at 38 sites. Enrollment
occurred between December 2003 and June 2005. Standard follow-up interval examinations were prescribed at 1 month,
6 months, 1 year, and annually thereafter. These endovascular results were compared with retrospective open surgical
data from three centers of excellence.
Results: The Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic
Aortic Aneurysms (VALOR) trial enrolled 195 patients, and 189 were identified as retrospective open surgical subjects.
Compared with the open surgery group, the VALOR test group had similar age and sex distributions, but had a smaller
TAA size. Patients received a mean number of 2.7  1.3 stent graft components. The diameters of 25% of the proximal
stent graft components implanted were <26 mm or >40 mm. Left subclavian artery revascularization was performed
before the initial stent graft procedure in 5.2% of patients. Iliac conduits were used in 21.1% of patients. In 33.5% of
patients, the bare spring segment of the most proximally implanted device was in zones 1 or 2 of the aortic arch. In 194
patients (99.5%), vessel access and stent graft deployment were successful at the intended site. The 30-day VALOR results
included perioperative mortality, 2.1%; major adverse advents, 41%; incidence of paraplegia, 1.5%; paraparesis, 7.2%; and
stroke, 3.6%. The 12-month VALOR results included all-cause mortality, 16.1%; aneurysm-related mortality, 3.1%;
conversion to open surgery, 0.5%; target aneurysm rupture, 0.5%; stent graft migration >10 mm, 3.9%; endoleak
(12.2%), stent graft patency, 100%; stable or decreasing aneurysm diameter, 91.5%; and loss of stent graft integrity, four
patients. No deployment-related events or perforation of the aorta by a graft component occurred. The Talent Thoracic
Stent Graft showed statistically superior performance with respect to acute procedural outcomes (P < .001), 30-day
major adverse events (41% vs 84.4%, P < .001), perioperative mortality (2% vs 8%, P < .01), and 12-month
aneurysm-related mortality (3.1% vs 11.6%, P < .002) vs open surgery.
Conclusions: The pivotal VALOR 12-month trial results demonstrate that the Medtronic Talent Thoracic Stent Graft
System is a safe and effective endovascular therapy as an alternative to open surgery in patients with TAA who were
considered candidates for open surgical repair. ( J Vasc Surg 2008;48:546-54.)Conventional open repair of a descending thoracic
aortic aneurysm (TAA) remains a major invasive surgical
procedure with significant inherent risk. These operations
require thoracotomy, aortic clamping, partial aortic bypass
to support the circulation, and considerable blood loss with
associated transfusions. The surgical mortality rate may
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546approach 12% even when performed by experienced sur-
geons in patients with good cardiac reserve and who are
deemed excellent surgical candidates.1 Perioperative mor-
bidity in this referenced cohort included spinal cord isch-
emia in 14%, respiratory failure in 20%, and renal insuffi-
ciency in 13% of patients undergoing open repair. These
results have been achieved in centers of excellence using an
experienced multidisciplinary team both intraoperatively as
well as postoperatively, and may not be widely reproduc-
ible.
Physicians have embraced thoracic endograft technol-
ogy with greater zeal than after United States Food and
Drug Administration (FDA) approval of the first endovas-
cular devices to treat abdominal aortic aneurysms. The
Medtronic Vascular Talent Thoracic Stent Graft System
(Medtronic Vascular, Santa Rosa, Calif) is a minimally
invasive endovascular device that offers an alternative treat-
ment for patients with TAA. This report summarizes the
pivotal 30-day and 12-month results of the Evaluation of
theMedtronic Vascular Talent Thoracic Stent Graft System
for the Treatment of Thoracic Aortic Aneurysms (VALOR)
neury
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Graft System in patients with TAAs. These endovascular
results are compared with retrospective open surgical data
from three centers of excellence: The Cleveland Clinic
Foundation (Cleveland, Ohio), Massachusetts General
Hospital (Boston, Mass), and The Hospital of the Univer-
sity of Pennsylvania (Philadelphia, Pa).
METHODS
Enrollment. The VALOR trial was a prospective,
nonrandomized, multicenter clinical study conducted in
the United States to evaluate the safety and efficacy of the
Medtronic Vascular Talent Thoracic Stent Graft in the
treatment of thoracic aortic diseases. Enrollment occurred
fromDecember 2003 to June 2005 at 38 institutions across
the United States (Appendix 1, online only). This report
focuses on the pivotal test group population, which in-
cluded patients diagnosed with TAAs. These patients were
considered candidates for open surgical repair and were low
to moderate risk (0, 1, and 2) per the modified Society for
Vascular Surgery and the American Association for Vascular
Surgery criteria (Appendix 2, online only).2 The anatomic
and medical inclusion and exclusion criteria are presented
in Table I.
Surgical candidates with a fusiform thoracic aortic an-
eurysm 5 cm or 2 times the diameter of the nonaneu-
Table I. Anatomic and medical inclusion and exclusion cr
Inclusion criteria
● Age between 18 and 85
● SVS/AAVS criteria 0, 1, or 2
● Women with negative pregnancy test 7 days before implant
● Fusiform focal TAA 5 cm or 2 times nonaneurysmal aorta a
● TAA 20 mm distal to origin of left common carotid artery and
● Proximal and distal neck diameter 18 to 42 mm
● Proximal and distal aneurysm neck length 20 mm
● TAA confirmed by CTA/MRA with optional three-dimensiona
● Subject must be able and willing to undergo follow-up imaging
Exclusion criteria
● Planned placement of the covered portion of the stent graft in z
● Access vessel precludes safe insertion of the delivery system
● Planned aortic conduit
● TAA with contained rupture
● Connective tissue disease (eg, Marfan syndrome, medial degene
● Mycotic aneurysm or is suspected of having systemic infection
● Previous stent and/or stent graft or previous surgical repair in t
● Treatment of an infrarenal aneurysm at the time of implant
● Previous surgical or endovascular treatment of an infrarenal aor
● History of bleeding diathesis, coagulopathy, or refuses blood tr
● Vascular interventional procedure or major surgery 30 days bef
● Planned vascular interventional procedure or major surgery 3
● Cerebrovascular accident 3 months
● Currently participating in an investigational drug or device clin
● Known allergy or intolerance to the device components
● Known hypersensitivity or contraindication to anticoagulants o
● Significant and/or circumferential aortic mural thrombus at pro
● Medical condition that may cause noncompliance with the prot
1year
CTA, Computed tomography angiography; DTA, descending thoracic ao
Surgery/American Association for Vascular Surgery; TAA, thoracic aortic arysmal aorta, as well as focal saccular thoracic aneurysms(penetrating atherosclerotic ulcers), were considered for
inclusion. The aneurysm had to be at least 20 mm distal to
the left common carotid and 20 mm proximal to the celiac
artery, have a proximal and distal nonaneurysmal aortic
neck diameter of between 18 and 42mm, and proximal and
distal nonaneurysmal aortic neck lengths of at least 20 mm.
A notable exclusion criterion was previous surgical or en-
dovascular treatment of an infrarenal aortic aneurysm.
Device description and deployment. The Talent
Thoracic StentGraft System consists of a preloaded stent graft
and theCoilTrac delivery system (Medtronic). The implanted
endoprosthetic portion of the Talent system is composed of a
polyester graft fabric sewn to a self-expanding nickel-titanium
(chemically polished nitinol) wire frame (Fig 1). Catalog and
custom stent graft configurations were made available for
this trial (Appendix 3, online only). Stent graft oversizing of
2 to 4 mm relative to the native aortic diameter (measured
as adventitia to adventitia) was recommended to provide
the necessary outward radial force, maintaining stent graft
apposition against the aortic wall. Preoperative diameter
and length measurements were obtained from detailed
computed tomography angiography (CTA) or magnetic
resonance angiography (MRA). The overall design concept
is modular, such that additional main sections as well as
proximal and distal extensions are introduced separately
and mated in vivo as needed to complete the exclusion of
r focal saccular TAA or penetrating atherosclerotic ulcer
m proximal to the origin of the celiac artery
nstruction 3 months before screening
examinations at 1, 6, and 12 months, and annually thereafter
0 or 1
n)
A
eurysm
sions
rollment
s of the implant procedure
ial
rast media, which is not amenable to pretreatment
l or distal attachment sites
confound the data interpretation, or a limited life expectancy of
RA, magnetic resonance angiography; SVS/AAVS, Society for Vascular
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iliac artery, tracks through the vasculature, and delivers the
stent graft at the target site. Deployment of the proximal
stent graft occurs as the outer sheath is withdrawn, initially
exposing the proximal bare spring and first covered stent
graft. A minimum overlap of 30 mm was required for
multiple stent grafts, and the Reliant balloon catheter
(Medtronic) could be used at the discretion of the physician
Fig 1. A, The Talent Thoracic Stent Graft Device consists of a
polyester graft fabric sewn to a self-expanding nickel-titanium
(chemically polished nitinol) wire frame. B, The modular design
concept of the Talent Thoracic Stent Graft Device is illustrated.to model the stent graft against the aortic wall. Adjunctivesurgical techniques, including iliac artery conduits, spinal
drains, and left subclavian artery (LSA) revascularization
were left to the discretion of the investigator.
The study protocol was approved by the FDA and site
institutional review boards. Patients signed an informed
consent before participation in the investigational study.
Follow-up protocol. Standard follow-up evaluations
were performed at 1, 6, and 12 months, and annually
thereafter. Follow-up visits included a CT scan, chest radio-
graph, and physical examination. All clinical data were
reported by the investigative center on case report forms
and monitored by the sponsor. A Clinical Events Commit-
tee adjudicatedmajor adverse events (MAEs) for device and
procedure relatedness. Medical Metrx Solutions (M2S;
West Lebanon, NH) served as the imaging core laboratory
and provided critical and comprehensive data evaluation of
all imaging studies, ensuring third-party assessment of graft
effectiveness.
Endoleaks were defined according to the well-established
type I to IV nomenclature.3 In the event the core labora-
tory could not identify the source, the endoleak was classi-
fied as unknown. Migration was defined as 10 mm prox-
imal or distal movement of the stent graft relative to fixed
anatomic landmarks, and aneurysm expansion was defined
as 5-mm increase in diameter from the 1-month to 12-
month follow-up visit. AnMAEwas defined as death due to
the procedure, any death 30 days of the procedure,
respiratory complications, renal insufficiency or failure, car-
diac events, neurologic events, aneurysm rupture, bowel
ischemia, major bleeding, or vascular complications. A
MAE that was identified as a serious adverse event by the
clinical investigator was defined as serious MAE.
Aneurysm-related death was defined as any death 30
days from initial implantation or occurring as a conse-
quence of an aneurysm rupture, a conversion to open
repair, or any other secondary endovascular procedure rel-
ative to the aneurysm that was treated by the Talent Tho-
racic Stent Graft System as evidenced by CT scan, angiog-
raphy, or direct observation at surgery or autopsy.
Excluded were aneurysms in anatomic areas other than the
targeted segment treated by the Talent Thoracic Stent
Graft System. Aneurysm-related death after open repair
included any death 30 days from the surgical procedure
or any death caused by reintervention of the targeted aortic
segment, or by complications related to the graft or the
procedure.
Summary statistics presented for categoric variables are
the number in each category and the percentage of known
values that this number represents. For continuous vari-
ables, the mean and standard deviation are provided; P
values were calculated using standard t tests. In some cases
the median is provided as well. Kaplan-Meier curves were
used to plot freedom from event over time.
RESULTS
Demographics. The VALOR trial enrolled 195 pa-
tients. Fig 2 details patient accountability of the 195 test
group patients at 12 months of follow-p. A total of 189
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 3 Fairman et al 549patients were identified as retrospective open surgical sub-
jects. Subject demographics, baseline history, and aneu-
rysm dimensional characteristics for VALOR test group
Fig 2. Flow chart shows follow-up for participants in the partici-
pants Evaluation of the Medtronic Vascular Talent Thoracic Stent
Graft System for the Treatment of Thoracic Aortic Aneurysms
(VALOR) trial.
Table II. Subject demographics: VALOR test group vs
open surgery
Variable VALOR test group Open surgery
Age
Total Population
N 195 189
Mean  SD (years) 70.2  11.1 69.6  9.1
Median 73.0 71.0
Min-Max 27-86 27-85
Male
N 115 99
Mean  SD (years) 69.3  11.7 69.9  8.5
Median 72.0 71.0
Min-Max 27-85 40-84
Female
N 80 90
Mean  SD (years) 71.6  10.1 69.3  9.8
Median 74.0 71.0
Min-Max 38-86 27-85
Sex, % (No.)
Males 59.0 (115) 52.4 (99)
Females 41.0 (80) 47.6 (90)
Ethnicity, % (No.)
White, non-Hispanic 83.1 (162) 93.7 (177)
Black, non-Hispanic 12.8 (25) 5.8 (11)
Hispanic (white or black) 2.6 (5) 0.5 (1)
Asian/Pacific Islander 1.0 (2) 0 (0)
Native American 0 (0) 0 (0)
Othera 0.5 (1) 0 (0)
SD, standard deviation; VALOR, Evaluation of the Medtronic Vascular
Talent Thoracic Stent Graft System for the Treatment of Thoracic Aortic
Aneurysms.
aOne subject had ethnicity specified as “none given.”and the open surgery group are presented in Tables II, III,and IV. Compared with the open surgery group, the sub-
jects in the VALOR test group had similar age and gender
distributions but had lower TAA size and were less likely to
have a previous abdominal aortic aneurysm (AAA) or AAA
repair. At the time of enrollment, 51 of 195 patients (26%)
in the VALOR test group had aneurysm-related symptoms.
The mean aneurysm length was 121.4  72.7 mm as
measured by the core laboratory. These data were not
available for the open surgery group.
Procedure and hospital course. Vessel access and
deployment of the study device at the intended site was
successful in 194 (99.5%) of the 195 patients enrolled in the
VALOR trial. One patient did not receive a study device
because of access failure. Iliac conduits were required for
arterial access in 21.1% of the patients. A mean number of
2.7  1.3 stent graft devices (range, 1-7) were implanted
per patient. Approximately 25% of the patients had proxi-
mal main Talent Thoracic Stent Graft components im-
planted with diameters26 mm (3 patients, 1.9%) or40
mm (49 patients, 23.2%). The highest implantation zone
(Fig 3) of the bare spring segment of the most proximally
implanted device was zone 1 in 6.7% of patients, zone 2 in
Table III. Baseline medical history: VALOR test group
vs open surgery
Medical history
VALOR test group
% (m/n)
Open surgery
% (m/n)
Cardiovascular
Angina 14.4 (28/195) 22.8 (26/114)
Arrhythmias 26.7 (52/195) 20.3 (37/182)
Congestive heart failure 8.7 (17/195) 11.2 (21/187)
CABG 10.3 (20/195) 13.3 (25/188)
Coronary artery disease 40.5 (79/195) 49.2 (91/185)
Hypertension 87.2 (170/195) 88.8 (166/187)
Myocardial Infarction 13.8 (27/195) 20.9 (39/187)
Peripheral vascular
disease 16.4 (32/195) 37.4 (70/187)
AAA 19.0 (37/195) 37.0 (70/189)
AAA repair 2.1 (4/195) 27.5 (52/189)
Gastrointestinal conditions 53.8 (105/195) NA
Renal insufficiency 17.4 (34/195) 16.0 (30/187)
Musculoskeletal conditions 53.8 (105/195) NA
Neurologic
Cerebral vascular
accident 9.7 (19/195) 13.4 (25/186)
Paraplegia 1.0 (2/195) 0.5 (1/186)
Paraparesis 0.5 (1/195) NA
Transient ischemic
attack 7.7 (15/195) NA
Pulmonary
COPD 36.9 (72/195) 42.6 (80/188)
Tobacco use 76.9 (150/195) 75.9 (142/187)
Other abnormal body
systems
Hyperlipidemia 43.6 (85/195) NA
Diabetes 15.9 (31/195) 8.6 (16/187)
Bleeding disorders 2.6 (5/195) NA
AAA, Abdominal aortic aneurysm repair; CABG, coronary artery bypass
grafting; COPD, chronic obstructive pulmonary disease; NA, not available;
VALOR, Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms.26.8%, zone 3 in 35.6%, and zone 4 in 30.9%.
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implanting physician and was performed before the initial
stent graft procedure in 10 of 194 patients (5.2%).4 At the
Fig 3. Zones of stent graft implantation for thoracic aortic an-
eurysms.
Table IV. Baseline maximum aneurysm diameters:
VALOR test group vs open surgery
Aneurysm
diameter,
mm
Site reported,
% (m/n)a
Core lab
reported,
% (m/n)b
Open surgery, %
(m/n)
10-17 0 (0/188) 0 (0/187) 0 (0/189)
18-29 0 (0/188) 0.5 (1/187) 0 (0/189)
30-39 4.3 (8/188) 7.5 (14/187) 0 (0/189)
40-49 10.6 (20/188) 20.3 (38/187) 0.5 (1/189)
50-59 34.6 (65/188) 34.8 (65/187) 13.8 (26/189)
60-69 33.5 (63/188) 24.6 (46/187) 40.7 (77/189)
70-79 12.2 (23/188) 10.2 (19/187) 24.3 (46/189)
80-89 3.2 (6/188) 2.1 (4/187) 16.9 (32/189)
90-99 1.1 (2/188) 0 (0/187) 0.5 (1/189)
100-109 0.5 (1/188) 0 (0/187) 1.6 (3/189)
110-119 0 (0/188) 0 (0/187) 0.5 (1/189)
120 0 (0/188) 0 (0/187) 1.1 (2/189)
VALOR, Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms.
aDenominator is 188 subjects with site reported data.
bDenominator is 187 subjects with evaluable scans.conclusion of the procedure, the 194 patients with a deviceimplanted had patent stent grafts, with integrity maintained
and freedom from twisting or kinking.
Clinical utility measures for the VALOR test group and
the open surgery group are compared in Table V. The
VALOR test group showed superiority in regards to sub-
jects requiring blood transfusion, procedural blood loss,
and length of procedure, as well as intensive care unit and
overall hospital stay (P  .001).
Mortality. Four of 195 VALOR patients (2.1%) died
30 days after implantation. Causes of death for these
patients included atheroembolic multisystem failure,
stroke, periprocedural cardiac arrest, and complications
from a myocardial infarction and perforated ulcer. Table VI
describes the 30-day mortality rates for the VALOR test
group compared with the open surgery group. The
VALOR test group experienced a significantly lower rate of
early mortality (2% vs 8%, P  .01). All-cause mortality at
12 months is presented in Table VII (16.1% vs 20.6%, P 
NS). Freedom from all-cause mortality is presented for
both groups in Fig 4. Predictors of all-cause mortality at 12
months in the VALOR patients included prior stroke, with
an odds ratio of 4.45 (P  .019), chronic obstructive lung
disease, with an odds ratio of 3.72 (P  .008), and aneu-
rysm length, with an odds ratio of 1.008 (P  .017) for
each additional millimeter.
Aneurysm-related mortality. Six of 192 patients
(3.1%) in the VALOR test group died of an aneurysm-
related cause through 12 months of follow-up. Four pa-
tients died30 days of the procedure. Two additional late
deaths were adjudicated as aneurysm-related. In the open
surgery group, 22 of 189 patients (11.6%) died of aneurysm-
related causes, and this difference was statistically significant
at P  .002. Freedom from aneurysm-related death for
both groups is presented in Fig 5.
Conversion to surgery. One patient (0.5%) was con-
verted to open surgical repair approximately 9 months after
implantation for complications related to an apparent in-
fection in the stented segment of the aorta. This patient was
alive and fully evaluable at the 12-month postimplantation
follow-up.
Major adverse events. One or more MAEs occurred
in 41% (80 of 195) of the VALOR patients 30 days
after implantation compared with 84.4% (151 of 179) in
the open surgery group (P  .001; Table VIII). Most of
the individual MAE categories in the endovascular group
were lower, but vascular complications were higher in
the VALOR patients, at 21% (41 of 195), compared with
the open surgery patients, at 12.3% (22 of 179). Freedom
from MAEs is presented in Fig 6.
Cerebrovascular accidents. Seven VALOR patients
(3.6%) had a periprocedural stroke. Three patients had
resolution of stroke-related disability at 12 months, death,
or last follow-up. Logistic regression analysis was per-
formed on the occurrence of stroke 30 days after the
implantation procedure. Patients who had a history of AAA
had an odds ratio of 7.1 for the occurrence of stroke (P 
.031), and implantation in zone 1 or zone 2 had an odds
ratio of 15.2 for the occurrence of stroke (P  .018).
ta.
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30 days in three of 195 VALOR patients (1.5%) and in a
fourth patient at 32 days after implantation. All patients had
placement of a lumbar drain at the time neurologic deficits
were identified. None of these patients experienced recov-
ery at the 1-year follow-up or by the time of death, and
none of the patients with paraplegia had a previously
treated AAA. Onset of paraparesis occurred30 days in 14
VALOR patients (7.2%). The proportion of patients with
unresolved paraparesis within 12 months or last known
follow-up fell to 3.1% (6 of 192).
Logistic regression analysis was performed on the inci-
dence of paraplegia or paraparesis within30 days after the
implantation procedure. The only covariate that was found
to be a significant predictor was the use of a conduit for
access, with an odds ratio of 4.13 (P  .020).
Stent graft effectiveness. The core laboratory identi-
fied seven patients with a type I endoleak by the 30-day
follow-up visit, as noted in Table IX. Most endoleaks were
type II. Sixteen patients had 17 additional endovascular
procedures, of which two procedures (1.0%) occurred in
the 30-day period before discharge, and 15 procedures
(8.1%) occurred at 31 to 365 days. Fourteen procedures
Table V. Acute procedural data: VALOR test group vs op
Variable VA
Subjects requiring blood transfusion, % (m/n) 2
Blood loss during procedure, mean  SD mLb 3
Duration of implant procedure, mean  SD min 1
Length of stay, mean  SD
ICU (accessible subjects), hours
Overall hospital, days
SD, Standard deviation; VALOR, Evaluation of the Medtronic Vascular Tale
aFor difference between groups. Percentage of subjects requiring blood tran
using the Wilcoxon test.
bOnly one open surgical site could provide blood loss during procedure da
Table VI. All-cause mortality at 30-days
Group 30-day mortality, % (m/n)a
VALOR test group 2.1 (4/195)
Open surgery 7.9 (15/189)
VALOR, Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms.
aP  .01.
Table VII. All-cause mortality at 12 months
Group 12 Month Mortality, % (m/n)a
VALOR test group 16.1 (31/192)
Open surgery 20.6 (39/189)
VALOR, Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms.
aP  .29.were performed to resolve an endoleak. One patient had aprocedure to resolve migration and to cover a pseudoaneu-
rysm. One patient was treated for an aneurysmal expansion,
and one patient was treated for a second aneurysm.
The core laboratory noted four stent graft migrations
12months. Twomigrations involved the proximal end of
the graft moving distally, and two involved the distal end of
the graft moving proximally. Only one patient required an
additional intervention related to the migration. Aneurysm
sac diameter was stable or shrinking in 91.4% of patients. In
11 patients (8.5%), the increase in maximal aneurysm di-
ameter was5 mm during this interval, and seven of these
patients had endoleaks during follow-up. No study patient
had loss of stent graft patency or instances of compression
or collapse of the endograft 12 months.
In two patients the core laboratory confirmed stent
fractures 12 months. Neither patient had adverse events
related to these fractures.
DISCUSSION
The Talent Thoracic Stent Graft System was first im-
planted in Australia in January 1996 and received the
Conformité Européene (CE) mark in April 1998. The
original device has undergone two iterative changes leading
up to this pivotal clinical trial, including a delivery system
change and chemical polishing of the nitinol stent. Most
importantly, the device has not been withdrawn from the
commercial market for any reasons related to safety or
effectiveness.
Data from worldwide experiences with the Talent Tho-
racic Stent Graft System have been reported in numerous
articles, which describe the use of the device in the whole
spectrum of thoracic aortic pathologies. Encouraging re-
sults in the elective treatment of thoracic aortic dissection
were first reported in 1999,5 followed by positive outcomes
in the emergency treatment of aortic perforations due to
ruptured TAA, type B aortic dissection, and traumatic
injury.6-8 The most comprehensive long-term experience
with the device was described by Fattori et al.9 In the
United States, Criado et al10 described their 8-year experi-
ence with the Talent Thoracic Stent Graft in 111 TAA
patients and 75 type B aortic dissection patients, with an
average follow-up of 40 months. The investigators found
lowmortality andmorbidity and favorablemidterm survival
urgery
test group Open surgery Pa
44/194) 93.7 (164/175) .001
 514.4 3054.9  1702.4 .001
 76.0 303.3  97.6 .001
 114.3 185.3  204.7 .001
 11.5 16.7  15.0 .001
oracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms.
were compared using the Fisher exact test. Other variables were compareden s
LOR
2.7 (
71.2
54.2
46.8
6.4
nt Th
sfusionresults.10 After FDA approval of the TAG thoracic endo-
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March 2005, and publication of the phase II multicenter
trial results,11 there has been rapid dissemination of this
technology.
The Talent Thoracic Stent Graft offers a wider range of
diameter options than is currently available in the commer-
cial United States market. Of the patients implanted with
diameters26 mm or40 mm, 25% would not have been
eligible for endovascular repair using commercially avail-
able devices owing to diameter sizing constraints.
In 33.5% of patients, the bare spring segment of the
Fig 4. Kaplan-Meier plot of freedom from all-cause mortality for
Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms
(VALOR) trial participants (solid line) and the open surgery co-
hort (dashed line).
Fig 5. Kaplan-Meier plot of freedom from aneurysm-related
mortality for Evaluation of the Medtronic Vascular Talent Tho-
racic Stent Graft System for the Treatment of Thoracic Aortic
Aneurysms (VALOR) trial participants (solid line) and the open
surgery cohort (dashed line).most proximally implanted device was in zones 1 or 2 of theaortic arch. The uncovered proximal stent allows for cross-
ing of the great vessels and proximal fixation in the arch
without occluding blood flow. There were no instances of
asymmetric opening or asymmetric deployment of the
proximal bare spring in this pivotal VALOR trial. In addi-
tion, there were no instances of erosion or perforation of
the aortic wall by the uncovered proximal nitinol stent.
Despite concerns about embolic stroke during endovascu-
lar maneuvers in the arch, the incidence of perioperative
stroke in this series was remarkably low at 3.6%, and nearly
half of these patients had resolution of stroke-related dis-
Table VIII. Major adverse events for VALOR test group
vs open surgery group at 30 days
Category
VALOR test
group % (m/n)
Open surgery %
(m/n)
Respiratory complications 13.3 (26/195) 46.9 (84/179)
Pneumonia 9.2 (18/195) 22.3 (40/179)
Pulmonary embolism 0.5 (1/195) 0.6 (1/179)
Pulmonary edema 2.1 (4/195) 24.6 (44/179)
Respiratory failure 6.2 (12/195) 26.8 (48/179)
Renal complications 6.2 (12/195) 29.1 (52/179)
Renal insufficiency 1.5 (3/195) 16.2 (29/179)
Renal failure 4.6 (9/195) 19.6 (35/179)
Cardiac complications 12.3 (24/195) 44.7 (80/179)
Myocardial infarction 1.5 (3/195) 5.6 (10/179)
Unstable angina 0.5 (1/195) 0.6 (1/179)
New arrhythmia 8.7 (17/195) 41.3 (74/179)
Exacerbation of CHF 3.1 (6/195) 5.6 (10/179)
Neurologic complications 11.8 (23/195) 20.1 (36/179)
New CVA/embolic
events 3.6 (7/195) 7.3 (13/179)
Paraplegia 1.5 (3/195) 3.4 (6/179)
Paraparesis 7.2 (14/195) 12.8 (23/179)
Gastrointestinal
complications 1.0 (2/195) 0.6 (1/179)
Bowel ischemia 1.0 (2/195) 0.6 (1/179)
Bleeding complications 15.4 (30/195) 48.0 (86/179)
Coagulopathy 5.6 (11/195) 20.1 (36/179)
Procedural/Postprocedural 14.4 (28/195) 37.4 (67/179)
Vascular complications 21.0 (41/195) 12.3 (22/179)
Expanding hematoma at
access site 1.5 (3/195) 2.2 (4/179)
Pseudo/false aneurysm
at access site 2.1 (4/195) 1.1 (2/179)
AV fistula 0.5 (1/195) 0 (0/179)
Retroperitoneal bleed 2.6 (5/195) 1.1 (2/179)
Thrombosis 0 (0/195) 6.1 (11/179)
Arterial occlusion 2.1 (4/195) 2.2 (4/179)
Vessel rupture/
dissection 6.2 (12/195) 1.7 (3/179)
Vessel disruption 7.7 (15/195) 0.6 (1/179)
Embolism 5.1 (10/195) 1.1 (2/179)
Re-op for limb ischemia 1.0 (2/195) 0.6 (1/179)
Vascular surgical repair
or ultrasound
compression required 14.4 (28/195) 3.4 (6/179)
Target lesion aneurysm
rupture 0 (0/195) 0.6 (1/179)
Total major adverse events 41.0 (80/195) 84.4 (151/179)
CHF, congestive heart failure; CVA, cerebrovascular accident; VALOR,
Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System
for the Treatment of Thoracic Aortic Aneurysms.ability at 12 months, death, or last follow-up.
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other thoracic endovascular devices as well as in association
with open thoracic aortic procedures. In the VALOR trial,
retrograde type A dissection developed in three of 195
enrolled patients (1.5%). In one of the patients, the core
laboratory determined that the proximal neck length was in
fact shorter than 10 mm, although this was not recognized
by the site investigators. In another patient the proximal
neck was also20 mm, and the core laboratory recognized
evidence of a chronic type B dissection, which was an
anatomic exclusion for enrollment in the pivotal arm. In the
third patient there was a proximal type I endoleak at the end
of the procedure and overzealous ballooning, which inad-
vertently included the proximal bare spring, was the likely
etiology. Further discussion of incidence and prevention of
retrograde type A dissection during thoracic aortic endo-
vascular procedures is beyond the scope of this article.
Although the delivery systems were mostly 24F and
25F in size, successful vessel access and deployment oc-
curred in 99.5% of cases, with iliac artery conduits used in
21%. A subset analysis failed to reveal any correlation be-
tween French size, conduit use, or vascular complications at
Fig 6. Kaplan-Meier plot of freedom from major adverse events
at 30 days for Evaluation of the Medtronic Vascular Talent Tho-
racic Stent Graft System for the Treatment of Thoracic Aortic
Aneurysms (VALOR) trial participants (solid line) and the open
surgery cohort (dashed line).
Table IX. Endoleaks at 1 and 12 months
(core laboratory)
Device-related event
At 1-month visit,
% (m/n)
At 12-month visit,
% (m/n)
Endoleak of any size 25.9 (45/174) 12.2 (15/123)
Type I 4.0 (7/174) 4.9 (6/123)
Type II 15.5 (27/174) 4.9 (6/123)
Type III 1.7 (3/174) 0 (0/123)
Type IV 0 (0/174) 0 (0/123)
Indeterminate 4.6 (8/174) 2.4 (3/123)30 days. The use of conduits in this study is comparable tothat reported in other contemporary series,12,13 and expe-
rience has dictated that vascular access complications are
frequent and may result in death. The need for conduits
should be anticipated before arterial injury, particularly in
elderly women with small, calcified, stenotic external iliac
arteries. Because the longest Talent covered device avail-
able for this pivotal trial was 116 mm, 2.7  1.3 devices
were placed per patient (range, 1-7 devices). Longer cov-
ered endografts (ie, 150 and 200 mm) would have resulted
in fewer devices placed per patient. Despite this, the inci-
dence of serious vascular complications in the VALOR
pivotal trial (Table IV) compares favorably with the Gore
TAG phase II multicenter trial in which longer endografts
were introduced and deployed through an indwelling 22F
or 24F sheath.
The 30-day paraplegia rate was low, and paraparesis was
moderately high in the acute phase. Despite the 30-day
paraparesis rate, this event carried a reasonably favorable
prognosis, as demonstrated by the unresolved paraparesis
rate of 3.1% at 12 months or last known follow-up. Strate-
gies potentially mitigating paraplegia, such as spinal drains,
were used at the discretion of the investigator when the
perceived risk was significant. An interesting observation is
that covariate analysis revealed conduit use was predictive
of paraplegia or paraparesis. This is consistent with pub-
lished reports defining retroperitoneal hemorrhage/hema-
toma, perioperative hypotension, and injury to the external
iliac artery as contributing factors for spinal cord isch-
emia.14 Future studies will need to identify effective peri-
operative spinal cord monitoring techniques and interven-
tions, as well as postoperative treatment algorithms.
Although a mean number of 2.7  1.3 stent graft
components (range, 1-7 devices) were implanted per pa-
tient, no junctional or type III endoleaks were detected at
the 12-month follow-up. After deployment, there were no
instances of loss of patency or stent graft collapse in this
cohort of patients with 12-month follow-up. Continued
follow-up of these patients will be necessary to document
the long-term efficacy of the device; however, several single-
center series using the Talent thoracic device have demon-
strated durability.15-17
The VALOR trial results support the use of the Talent
Thoracic Stent Graft System as a safe and effective alterna-
tive to open surgical repair in patients with descending
TAAs. These elderly patients, despite their significant co-
morbidities, had lowmortality at 30 days and 12months, as
well as aneurysm-related mortality at 12 months, support-
ing a high rate of successful aneurysm treatment. Specifi-
cally, the device showed statistically superior performance
with respect to acute procedural outcomes, 30-day MAEs,
perioperative mortality, and 12-month aneurysm-related
mortality compared with open surgery. These data are
particularly meaningful given that the open surgery data
were derived from high-volume centers with a reputation
for surgical excellence and where the best surgical out-
comes would be anticipated.
A review of the recent medical literature allows for
comparison between the Talent Thoracic Stent Graft expe-
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estimates.18,19 Similar rates in 30-day and 12-month all-
cause mortality and 12-month aneurysm-related mortality
rates have been reported. When serious MAE rates are
compared through 12 months by organ system, the
VALOR test group and the subjects with a Gore TAG
device have essentially the same profile ofMAE rates. These
comparisons demonstrate that despite fundamental differ-
ences in stent graft design, the Talent Thoracic Stent Graft
as used in the VALOR test group performed in a substan-
tially similar manner to the Gore TAG device when im-
planted in a similar group of study subjects.
CONCLUSIONS
The Talent Thoracic Stent Graft System has demon-
strated reasonable assurance of safety and effectiveness in
treating patients with aneurysms of the descending thoracic
aorta who are open surgical candidates with low to moder-
ate surgical risk. The VALOR trial data demonstrate that
endovascular therapy with this device results in lower peri-
operative death, 12-month aneurysm-related death, and
lower rates of morbidity than open surgery. Vascular com-
plications associated with thoracic aortic endovascular in-
terventions, including vessel disruption, dissection, rup-
ture, and embolism, are higher than in open surgery and
demonstrate the need for further refinement of endovascu-
lar thoracic delivery systems. Reduced blood loss and time
in intensive care and overall hospital length of stay continue
to represent additional advantages of endografting vs open
surgical repair. The benefits of the device clearly outweigh
the risks when considering the clinically significant results
of the VALORTrial conducted in the intended population.
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Principal investigator Site City
Ronald Fairman, MD Hospital of the University of Pennsylvania Philadelphia, Pa
Mark Farber, MD University of North Carolina Chapel Hill, NC
Christopher Kwolek, MD Massachusetts General Hospital Boston, Mass
Michael Dake, MD University of Virginia Charlottesville, Va
Frank Criado, MD Union Memorial Hospital Baltimore, Md
David Williams, MD University of Michigan Ann Arbor, Mich
Zvonimir Krajcer, MD St Luke’s Episcopal Hospital - Houston Houston, Tex
Alan Lumsden, MD Baylor College of Medicine Houston, Tex
Manish Mehta, MD Albany Medical Center Albany, NY
Robert Rhee, MD Shadyside Hospital - UPMC Pittsburgh, Pa
Anthony Lee, MD University of Florida Gainesville, Fla
Sean Lyden, MD Cleveland Clinic Foundation - Ohio Cleveland, Ohio
Jim Swischuk, MD St Francis Hospital Peoria, Ill
Paul Bove, MD William Beaumont Hospital Royal Oak, Mich
Rodney White, MD Harbor UCLA Torrance, Calif
Edward Garrett, MD Baptist Memorial Hospital Memphis, Tenn
Michael Tuchek, DO Loyola University Medical Center Maywood, Ill
Kim Hodgson, MD Memorial Medical Center Springfield, Ill
Robert Allen, MD Physician’s Regional Medical Center Naples, Fla
Phillip Allmendinger, MD Hartford Hospital Hartford, Conn
Mark Bates, MD Charleston Area Medical Center Charleston, WV
Daniel Benckart, MD Allegheny General Hospital Pittsburg, Pa
Tom Bower, MD Mayo Clinic- Rochester Rochester, Minn
Mark Eskandari, MD Northwestern Memorial Hospital Chicago, Ill
Neal Cayne, MD NYU Vascular Associates New York, NY
Peter Faries, MD New York Presbyterian Cornell University New York, NY
Mark Fillinger, MD Dartmouth- Hitchcock Medical Center Lebanon, NH
Marc Glickman, MD Sentara Norfolk General, Vascular, and Transplant Specialists Norfolk, Va
Matthew Jung, MD Surgical Care Associates Louisville, Ky
Barry Katzen, MD Baptist Hospital of Miami Miami, Fla
Lowell Satler, MD Washington Hospital Center Washington, DC
Richard McCann, MD Duke University Medical Center Durham, NC
Takao Ohki, MD Montefiore Medical Center Bronx, NY
Venkatesh Ramaiah, MD Arizona Heart Institute Phoenix, Ariz
Timothy Roush, MD Carolinas Medical Center Charlotte, NC
Gregorio Sicard, MD Washington University School of Medicine St Louis, Mo
Cary Stowe, MD Florida Hospital Orlando, Fla
Christopher Zarins, MD Stanford University Stanford, Calif
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comorbidity grading system
Component
Society for Vascular Surgery risk factor
0 (Absent) 1 (Mild) 2 (Moderate) 3 (Severe)
Age, years 55 55-69 70-85 85
Hypertension None (cutoff: DBP
usually 90 mm
Hg)
Controlled (cutoff:
point DBP 90 mm
Hg) with single drug
Controlled with 2 or
more drugs
Uncontrolled hypertension
Cardiac Asymptomatic, with
normal ECG
Asymptomatic, but with
either remote MI by
history (6 months),
occult MI by ECG,
or fixed deficit on
dipyridamole thallium
or similar scan
Any one of the
following:
● stable angina
● no angina but signifi-
cant reversible perfu-
sion deficit on Dip-
Thal
● significant silent isch-
emia (1% of time) on
Holter monitoring
● EF 25%-45%
● controlled ectopy or
asymptomatic ar-
rhythmia
Any one of the following:
● unstable angina
● symptomatic or poorly con-
trolled ectopy or arrhythmia
(chronic/recurrent)
● poorly compensated or recurrent
CHF
● EF 25%
● MI 6 mon with no interven-
tion (CABG, angioplasty or
stenting)
Pulmonary Asymptomatic,
normal chest x-
ray, PFT 20%
of predicted
Asymptomatic or mild
dyspnea on exertion,
mild chronic
parenchymal x-ray
changes, PFT
65%-80% of predicted
Between 1 and 3 Vital capacity 1.85 L, FEV1 1.2
L or 35% of predicted, maximal
voluntary ventilation 50% of
predicted, PCO2 45 mm Hg,
supplemental O2 medically
necessary, or pulmonary
hypertension
CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; Dip-Thal, dipyridamole thallium scan; ECG, electrocardiogram; EF, ejection fraction;
FEV1, forced expiratory volume in 1 second; MI, myocardial infarction; PFT, pulmonary function tests.Appendix 3 (online only). Catalog stent graft specifications and configurations
Variables Main sections
Additional distal
main sections Proximal extensions Distal extensions
Diameters (2-mm increments)
Proximal 22-46 26-46 26-46 26-46
Distal 22-46 22-44 26-46 26-46
Total covered length of device, mma 112-116 110-114 46-54 46-54
Proximal configurations FreeFlob (Bare Spring) Open Web FreeFlob Open Web
Distal configurations Closed Web Closed Web Open Web Bare Springb
aThe maximum total length cannot exceed 130 mm.
b“Bare Spring” and “FreeFlo” refer to the configuration in which the terminating spring has no fabric coverage. Bare Spring is the term used for devices having
a proximal diameter 24 mm, while FreeFlo is the term used for devices having a proximal diameter 24 mm. FreeFlo devices feature a support spring to
prevent fabric infolding.
